Condition: Primary Open Angle Glaucoma · Sponsor: Santen SAS
The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥18 mmHg and ≤35 mmHg and/or where glaucoma progression warrants surgery.
This description comes directly from the study's public registry record.
Study Director / Medical Monitor Raymund Angeles · 510-368-9861 · raymund.angeles@santen.com
Santen SAS Clinical Operations · bianca.groenendijk@santen.com
Always discuss trial participation with your own doctor first.
| AKH Wien | Vienna, Austria | Recruiting |
| Glaucoma Clinic, UZ Leuven | Leuven, Belgium | Recruiting |
| Internationale Innovative Opthalmochirurgie GbR | Düsseldorf, Germany | Recruiting |
| Universitätsklinikum Tübingen, Department für Augenheilkunde | Tübingen, Germany | Not Yet Recruiting |
| Irccs Fondazione G. B. Bietti | Rome, Italy | Recruiting |
| Policlinico Universitario Molinette | Turin, Italy | Not Yet Recruiting |
| Universiteitskliniek voor Oogheelkunde Maastricht | Maastricht, Netherlands | Not Yet Recruiting |
| ULS Santa Maria, Lisboa | Lisbon, Portugal | Not Yet Recruiting |
| Hospital Clinico San Carlos | San Carlos, Spain | Not Yet Recruiting |
| Guy's and St. Thomas' NHS Foundation Trust | London, United Kingdom | Recruiting |
| Moorfields Eye Hospital NHS Foundation Trust | London, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07235592